AbbVie beats second-quarter earnings projections as Humira competitors see slow uptake - Endpoints News endpts.com Submitted by endpointsnews6292 on July 27, 2023 at 3:21 PM in business No comments 10
'An unholy union': Stanford scientists create a drug that flips cancer driver into killer - Endpoints News endpts.com Submitted by endpointsnews6292 on July 27, 2023 at 1:45 PM in health No comments 24
ViiV's long-acting HIV injectable Cabenuva preferred over Biktarvy by 90% of patients in PhIII trial - Endpoints News endpts.com Submitted by endpointsnews6292 on July 24, 2023 at 7:04 PM in health No comments 29
FDA approves Daiichi Sankyo's new first-line AML drug quizartinib with boxed warning for heart disorders - Endpoints News endpts.com Submitted by endpointsnews6292 on July 21, 2023 at 11:07 AM in business No comments 19
Argenx launches $750M offering after PhII data drop - Endpoints News endpts.com Submitted by endpointsnews6292 on July 18, 2023 at 3:15 PM in business No comments 6
EU orders Illumina to pay $476M fine over unapproved Grail deal - Endpoints News endpts.com Submitted by endpointsnews6292 on July 12, 2023 at 10:09 AM in business No comments 53
In a first, FDA signs off on CellTrans' type 1 diabetes cell therapy days after industry's eyes fixated on Vertex data - Endpoints News endpts.com Submitted by endpointsnews6292 on June 29, 2023 at 10:46 AM in business No comments 45
FDA rejects higher dose of Regeneron blockbuster due to contractor issues - Endpoints News endpts.com Submitted by endpointsnews6292 on June 27, 2023 at 7:53 PM in business No comments 2
FDA's Peter Marks overrode reviewers' call to reject Sarepta's new Duchenne gene therapy - Endpoints News endpts.com Submitted by endpointsnews6292 on June 23, 2023 at 3:36 PM in business No comments 15